Bioinformatics Partnering Terms and Agreements

3rd Edition

Publication Date March 2013
ISBN n/a
Pages 1154
Tables n/a
Figures n/a

PDF £1850 $2900

Single user

 Add to Basket

Provides comprehensive insight into bioinformatics partnering deals and agreements entered into by leading healthcare companies.


The Bioinformatics Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the bioinformatics partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter bioinformatics partnering deals. The majority of deals are discovery stage whereby the licensee obtains a right or an option right to license the licensors bioinformatics technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest bioinformatics agreements announced in the healthcare sectors.
Bioinformatics is the application of computer science and information technology to the field of biology and medicine. Bioinformatics deals with algorithms, databases, information systems, web technologies, artificial intelligence, information and computation theory, software engineering, data mining, image processing, modeling, simulation, signal processing, discrete mathematics, control systems, and statistics, for generating new knowledge of biology and medicine.
Bioinformatics deals have increased in terms of popularity for partnering in the past decade, as computing power has been embraced in order to speed up the discovery, evaluation and clinical assessment processes.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all bioinformatics partnering deals announced since January 2007, including financial terms where available, including over 1500 links to online deal records of actual bioinformatics partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of bioinformatics dealmaking and business activities.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in bioinformatics dealmaking since 2007, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading bioinformatics deals since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of bioinformatics deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of bioinformatics partnering deals signed and announced since January 2007, where a contract document is available in the public domain. The chapter is organized by stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
In addition, a comprehensive appendix is provided organized by bioinformatics partnering company A-Z , deal type definitions and bioinformatics partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in bioinformatics partnering and dealmaking since 2007.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of bioinformatics technologies and products.

Bioinformatics Partnering Terms and Agreements provides the reader with the following key benefits:

  • In-depth understanding of bioinformatics deal trends since 2007
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of bioinformatics agreements with numerous real life case studies
  • Comprehensive access to over 1500 actual vaccine contracts entered into by the world's biopharma companies
  • Detailed access to actual bioinformatics contracts enter into by the leading fifty bigpharma companies
  • Insight into the terms included in a bioinformatics agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

 

Report scope
Bioinformatics Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to bioinformatics trends and structure of deals entered into by leading companies worldwide.
Bioinformatics Partnering Terms and Agreements includes:

  • Trends in bioinformatics dealmaking in the biopharma industry since 2007 o Analysis of bioinformatics deal structure
  • Access to headline, upfront, milestone and royalty data o Case studies of real-life bioinformatics deals o Access to over 1500 bioinformatics contract documents
  • The leading bioinformatics deals by value since 2005 o Most active bioinformatics dealmakers since 2007
  • The leading bioinformatics partnering resources In Bioinformatics Partnering Terms and Agreements, the available contracts are listed by: o Company A-Z o Headline value
  • Stage of development at signing o Deal component type
  • Specific therapy target Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. The Bioinformatics Partnering Terms and Agreements report provides comprehensive access to available deals and contract documents for over 1,500 bioinformatics deals. Analyzing actual contract agreements allows assessment of the following:
  • What are the precise bioinformatics rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal? o How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned? o Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed? o How are disputes to be resolved?
  • Under what conditions can the deal be terminated? o What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed? o Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Bioinformatics Partnering Terms and Agreements provides the reader with the following key benefits:

  • In-depth understanding of bioinformatics deal trends since 2007
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of bioinformatics agreements with numerous real life case studies
  • Comprehensive access to over 1500 actual bioinformatics contracts entered into by the world's biopharma companies
  • Detailed access to actual bioinformatics contracts enter into by the leading fifty bigpharma companies
  • Insight into the terms included in a bioinformatics agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies
  • Executive Summary
  • Chapter 1 - Introduction
  • Chapter 2 - Trends in bioinformatics dealmaking
    • 2.1. Introduction
    • 2.2. Bioinformatics partnering over the years
    • 2.3. Bigpharma bioinformatics dealmaking activity
    • 2.4. Bigpharma not active in bioinformatics partnering
    • 2.5. Bioinformatics partnering by deal type
    • 2.6. Bioinformatics partnering by stage of development
    • 2.7. Bioinformatics partnering by disease type
    • 2.8. Average deal terms for bioinformatics partnering
      • 2.8.1 Bioinformatics partnering headline values
      • 2.8.2 Bioinformatics deal upfront payments
      • 2.8.3 Bioinformatics deal milestone payments
      • 2.8.4 Bioinformatics royalty rates
  • Chapter 3 - Leading bioinformatics deals
    • 3.1. Introduction
    • 3.2. Top bioinformatics deals by value
    • 3.3. Top bioinformatics deals involving bigpharma
  • Chapter 4 - Bigpharma bioinformatics deals
    • 4.1. Introduction
    • 4.2. How to use bigpharma bioinformatics partnering deals
    • 4.3. Bigpharma bioinformatics partnering company profiles
      • Abbott
      • Allergan
      • Amgen
      • Astellas
      • AstraZeneca
      • Baxter International
      • Bayer
      • Biogen Idec
      • Boehringer Ingelheim
      • Bristol-Myers Squibb
      • Daiichi Sankyo
      • Eisai
      • Eli Lilly
      • Galderma
      • GlaxoSmithKline
      • Grifols
      • Hospira 73
      • Johnson & Johnson
      • Merck & Co
      • Merck KGaA
      • Mitsubishi Tanabe
      • Novartis
      • Novo Nordisk
      • Otsuka
      • Pfizer
      • Purdue
      • Roche
      • Sanofi
      • Servier
      • Shire
      • Takeda
      • Teva
      • UCB
      • Valeant
  • Chapter 5 - Bioinformatics dealmaking directory
    • 5.1. Introduction
    • 5.2. By stage of development
      • Discovery
      • Formulation
      • Marketed
      • Phase I
      • Phase II
      • Phase III
      • Preclinical
      • Regulatory
    • 5.3. By deal type
      • Asset purchase
      • Bigpharma outlicensing
      • Co-development
      • Collaborative R&D
      • Co-market
      • Contract service
      • Co-promotion
      • CRADA
      • Cross-licensing
      • Development
      • Distribution
      • Equity purchase
      • Evaluation
      • Grant
      • Interests
      • Joint venture
      • Licensing
      • Litigation
      • Loan
      • Manufacturing
      • Manufacturing - OEM
      • Marketing
      • Option
      • Promotion
      • Research
      • Settlement
      • Spin out
      • Sub-license
      • Supply
      • Technology transfer
      • Termination
    • 5.4. By therapy area
      • Anaesthetics
      • Breast
      • Cardiovascular
      • Central Nervous System
      • Dental
      • Dermatology
      • Gastrointestinal
      • Genetic disorders
      • Genitourinary
      • Gynaecology
      • Hematology
      • Hospital care
      • Immunology
      • Infectives
      • Metabolic
      • Musculoskeletal
      • Obstetrics
      • Oncology
      • Ophthalmics
      • Pediatrics
      • Psychiatry
      • Public Health
      • Respiratory
      • Sensory organs
      • Sexual Health
  • Chapter 6 - Partnering resource center
    • 6.1. Online partnering
    • 6.2. Partnering events
    • 6.3. Further reading on dealmaking
  • About Wildwood Ventures
  • Current Partnering
  • Current Agreements
  • Current Reports
  • Recent report titles from Current Partnering
  • Order Form - Reports
    • Table of figures
    • Figure 1: Bioinformatics partnering since 2007
    • Figure 2: Bigpharma - top 50 - bioinformatics deals 2007 to 2013
    • Figure 3: Inactive bigpharma in bioinformatics partnering 2007-2012
    • Figure 4: Bioinformatics partnering by deal type since 2007
    • Figure 5: Bioinformatics partnering by deal type since 2007
    • Figure 6: Bioinformatics partnering by disease type since 2007
    • Figure 7: Bioinformatics partnering by oncology target since 2007
    • Figure 8: Bioinformatics deals with a headline value - by stage of development
    • Figure 9: Bioinformatics deal headline value distribution - discovery stage, US$million
    • Figure 10: Bioinformatics deal headline value distribution - preclinical stage, US$million
    • Figure 11: Bioinformatics deal headline value distribution - phase I stage, US$million
    • Figure 12: Bioinformatics deal headline value distribution - phase II stage, US$million
    • Figure 13: Bioinformatics deal headline value distribution - phase III stage, US$million
    • Figure 14: Bioinformatics deal headline value distribution - regulatory stage, US$million
    • Figure 15: Bioinformatics deal headline value distribution - marketed stage, US$million
    • Figure 16: Summary median headline value by stage of development, 2007-2013
    • Figure 17: Bioinformatics deals with upfront payment values - by stage of development
    • Figure 18: Bioinformatics deal upfront payment distribution - discovery stage, US$million
    • Figure 19: Bioinformatics deal upfront payment distribution - preclinical stage, US$million
    • Figure 20: Bioinformatics deal upfront payment distribution - phase I stage, US$million
    • Figure 21: Bioinformatics deal upfront payment distribution - phase II stage, US$million
    • Figure 22: Bioinformatics deal upfront payment distribution - phase III stage, US$million
    • Figure 23: Bioinformatics deal upfront payment distribution - regulatory stage, US$million
    • Figure 24: Bioinformatics deal upfront payment distribution - phase marketed stage, US$million
    • Figure 25: Summary median upfront value by stage of development, 2007-2013
    • Figure 26: Bioinformatics deals with milestone payments - by stage of development
    • Figure 27: Bioinformatics deal milestone value distribution, US$million - discovery stage
    • Figure 28: Bioinformatics deal milestone value distribution, US$million - preclinical stage
    • Figure 29: Bioinformatics deal milestone value distribution, US$million - phase I stage
    • Figure 30: Bioinformatics deal milestone value distribution, US$million - phase II stage
    • Figure 31: Bioinformatics deal milestone value distribution, US$million - phase III stage
    • Figure 32: Bioinformatics deal milestone value distribution, US$million - regulatory stage
    • Figure 33: Bioinformatics deal milestone value distribution, US$million - marketed stage
    • Figure 34: Bioinformatics deals with royalty rates- by stage of development
    • Figure 35: Bioinformatics deal royalty rates value distribution, US$million - discovery stage
    • Figure 36: Bioinformatics deal royalty rates value distribution, US$million - preclinical stage
    • Figure 37: Bioinformatics deal royalty rates value distribution, US$million - phase I stage
    • Figure 38: Bioinformatics deal royalty rates value distribution, US$million - phase II stage
    • Figure 39: Bioinformatics deal royalty rates value distribution, US$million - phase III stage
    • Figure 40: Bioinformatics deal royalty rates value distribution, US$million - regulatory stage
    • Figure 41: Bioinformatics deal royalty rates value distribution, US$million - marketed stage
    • Figure 42: Summary median milestone value by stage of development, 2007-2013
    • Figure 43: Top bioinformatics deals by value since 2007
    • Figure 44: Top bioinformatics deals signed by bigpharma value since 2007
    • Figure 45: Online partnering resources
    • Figure 46: Forthcoming partnering events